Change over period: —
NSE · POLYMED
POLY MEDICUR
-18.3% from the 52-week high · +38.9% above the low
Poly Medicure Ltd. engages in the provision and sales of medical devices. The company is headquartered in Faridabad, Haryana. The company went IPO on 2011-12-05. The firm is primarily in the business of manufacture and sale of medical devices. The firm offers a diverse portfolio of medical devices in the product verticals of infusion therapy, oncology, anesthesia and respiratory care, covid care, urology, gastroenterology, blood management and blood collection, surgery and wound drainage, dialysis, central venous access catheters, veterinary medical devices, and others. The company supplies its products to approximately 120 countries, in Europe, Africa, Americas, Australia, and Asia. Its products include suction control valve, safety arterial cannula, VTM Kit, VLTM kit, blood collection needle with flashback, and pre-filled syringes. The firm operate nine manufacturing facilities across India, China, Egypt, and Italy. In India, it operates six manufacturing facilities, four of which are situated at Faridabad (Haryana), and one each in Jaipur (Rajasthan) and Haridwar (Uttarakhand).
The short version. POLY MEDICUR reported revenue of ₹581 crore for Sep 2026, up 30.9% from a year earlier. Net profit was ₹95 crore (up 3.3% year on year). Return on equity was 10.4% in Mar 2026. Promoter holding was 62.41% in Sep 2026, down 0.02 points over 8 quarters.
1 · The price
How has the stock traded?
POLY MEDICUR trades 18.3% below its 52-week high and 38.9% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹581 cr.
Sep 2026 net profit of ₹95 cr.
4.3 pts lower than a year earlier.
Revenue compounded at 20.1% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 581 | 525 | 535 | 494 | 444 | 403 | 441 | 424 |
| Net profit | 95 | 86 | 66 | 71 | 92 | 93 | 92 | 85 |
| Net margin % | 16.4 | 16.4 | 12.4 | 14.4 | 20.7 | 23.1 | 20.8 | 20.1 |
| EPS (₹) | 9.39 | 8.49 | 6.54 | 7.0 | 9.06 | 9.19 | 9.06 | 8.41 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1875 | 1670 | 1376 | 1115 | 923 | 786 | 687 | 611 |
| Net profit | 322 | 339 | 258 | 179 | 147 | 136 | 96 | 65 |
| Net margin % | 17.2 | 20.3 | 18.8 | 16.1 | 15.9 | 17.3 | 14.0 | 10.7 |
| EPS (₹) | 31.78 | 33.41 | 26.91 | 18.69 | 15.28 | 14.17 | 10.86 | 7.41 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 10.4% in Mar 2026; debt to equity is 0.11.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 10.4 | 12.2 | 17.6 | 14.4 |
| Return on capital % | 13.2 | 16.3 | 23.4 | 19.0 |
| EBITDA margin % | 27.8 | 30.8 | 29.1 | 26.2 |
| Net margin % | 16.1 | 19.2 | 18.0 | 15.6 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 20.1% | 19.9% |
| Profit CAGR | 21.6% | 18.9% |
4 · The owners
Who holds it, and are they adding?
Down 0.02 pts over 8 quarters.
Down 6.98 pts over 8 quarters.
Up 4.24 pts over 8 quarters.
+25 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 62.43 | 62.43 | 62.43 | 62.41 | 62.41 | 62.41 | 62.41 | 62.41 | -0.02 |
| FII | 12.33 | 11.46 | 11.41 | 9.77 | 9.4 | 5.91 | 5.57 | 5.35 | -6.98 |
| DII | 11.66 | 11.96 | 11.72 | 13.54 | 13.84 | 15.59 | 16.08 | 15.9 | +4.24 |
| Public | 13.57 | 14.15 | 14.44 | 14.27 | 14.34 | 16.08 | 15.94 | 16.33 | +2.76 |
Mutual fund holdings · Oct 2026
78 schemes hold this stock
53 the month before.
- quant Small Cap Fund1.87% of NAV
- SBI Healthcare Opportunities Fund1.53% of NAV
- DSP Nifty Smallcap250 Quality 50 Index Fund1.44% of NAV
- SBI MNC Fund1.42% of NAV
- ITI Pharma and Healthcare Fund1.28% of NAV
- Invesco India Large cap Fund1.26% of NAV
- HSBC Midcap Fund1.07% of NAV
- Invesco India Equity Savings Fund1.0% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for POLY MEDICUR are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Healthcare Equipment & Supplies stocks
Quick answers
Common questions about POLY MEDICUR
What is the POLY MEDICUR share price?
POLY MEDICUR (POLYMED) last closed at ₹1,670.60, up 0.97% on the day. Its 52-week range is ₹1,191.10 to ₹2,025.30.
What is the market cap of POLY MEDICUR?
POLY MEDICUR has a market capitalisation of about ₹16,753 crore. Its price-to-earnings ratio is 52.8.
How are POLY MEDICUR's latest results?
POLY MEDICUR reported revenue of ₹581 crore for Sep 2026, up 30.9% from a year earlier. Net profit was ₹95 crore (up 3.3% year on year). Return on equity was 10.4% in Mar 2026. Promoter holding was 62.41% in Sep 2026, down 0.02 points over 8 quarters.
Who owns POLY MEDICUR?
As of Sep 2026, shareholding was: Promoter 62.41%, FII 5.35%, DII 15.9%, Public 16.33%.
How many mutual funds hold POLY MEDICUR?
78 mutual fund schemes held POLY MEDICUR in October 2026. That compares with 53 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 18 Sep 2025 · Final Dividend - Rs. 3.5
- 19 Sep 2024 · Final Dividend - Rs. 3
- 21 Sep 2023 · Final Dividend - Rs. 3
- 16 Sep 2022 · Final Dividend - Rs. 2.5
- 16 Sep 2021 · Dividend - Rs. 2.5
- 27 Feb 2020 · Interim Dividend - Rs. 2
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.